NDC product
M-M-R II
NDC 0006-4681 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-4681 |
|---|---|
| Proprietary name | M-M-R II |
| Nonproprietary name | measles, mumps, and rubella virus vaccine live |
| Substances | MEASLES VIRUS STRAIN ENDERS' ATTENUATED EDMONSTON LIVE ANTIGEN, MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN, RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION |
| Route | INTRAMUSCULAR, SUBCUTANEOUS |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA101069 |
| Pharmacologic classes | Actively Acquired Immunity [PE], Live Attenuated Measles Virus Vaccine [EPC], Live Attenuated Mumps Virus Vaccine [EPC], Live Attenuated Rubella Virus Vaccine [EPC], Measles Vaccine [CS], Mumps Vaccine [CS] and 3 more |
| Marketing start | Apr 21, 1971 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: